Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?

J Clin Pharmacol. 2017 Nov;57(11):1415-1418. doi: 10.1002/jcph.945. Epub 2017 May 25.

Authors

Jagannadha Avasarala¹, Sandip Jain¹, Enrique Urrea-Mendoza¹

Affiliation

¹ Department of Medicine, Division of Neurology, USC School of Medicine, Greenville Health System, Greenville, SC, USA.

PMID: 28543950
DOI: 10.1002/jcph.945

No abstract available

Keywords: disease management; drug information; immunopharmacology; neurology; pharmacovigilance.

MeSH terms

Brain / diagnostic imaging
Fingolimod Hydrochloride / adverse effects*
Humans
Immunosuppressive Agents / adverse effects*
Lymphopenia / chemically induced*
Lymphopenia / diagnostic imaging
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Product Surveillance, Postmarketing

Substances

Immunosuppressive Agents
Fingolimod Hydrochloride